Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aflac

Blackrock Inc

Discover

KeyCorp

Lockheed Martin

Norwood Financial

Realty Income Corp

Pfizer

AT&T

Target

Vanguard High Dividend Yield ETF

Growing your dividend income takes time and consistency. In December, we (my wife and I) received a total of $5,483.32 of dividend income.

Dividend Income Summary: Lanny's December 2020 Summary

AbbVie

Bristol-Myers

All three also offer attractive dividends.

Got $5,000? These 3 Stocks Are Ridiculously Cheap Right Now

Whether or not you believe that Viatris can make you rich depends on how strongly you believe in biosimilars.

Is Viatris a Millionaire-Maker Stock?

ALX Onconology Holdings Inc

Athene Holding Ltd. Class A

Biglari Hlds

Grid Dynamics Holdings Inc

Lexicon Pharmaceuticals

 StoneX Group

Southern National Bancorp of Virginia

Net 1 UEPS Technologies

AMERCO

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as has been the case as new COVID-19 cases surge.

Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More

PITTSBURGH, Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen® products. Viatris is extremely pleased...

Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi

PITTSBURGH, Dec. 15, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation ("TRC") to purchase up to 6,000,000 shares, or approximately 0.497 percent, of the outstanding common stock of Viatris at a price of $16....

Viatris Inc. Recommends Caution on TRC Capital Corp.'s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer

Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.

Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative

Shares of Viatris Inc. were down 0.2% in premarket trading on Friday after the company said it plans to close or divest up to 15 manufacturing sites and may cut up to 9,000 jobs, or 20% of its workforce, as part of a restructuring plan. Viatris is the name of the company formed a year ago by the merger of Mylan and Upjohn, the generics business previously owned by Pfizer Inc..

Viatris to cut up to 9,000 jobs

PITTSBURGH, Dec. 11, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced additional details of its previously disclosed multi-year global restructuring initiative. The restructuring initiative is part of the company's previously announced roadmap to maximize long-term value...

Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative

News for Viatris Stock (VTRS)